European regulators gave their blessing to a drug coated stent made by Medtronic this morning, clearing the way for the company to enter a market seen as extremely lucrative by many analysts. Industry analysts say the Endeavor stent could do extremely well if it performs as well as competitor's devices. The Minneapolis-based company will now compete with Johnson & Johnson and Boston Scientific for market share in a global market believed to be worth $5.5 billion. The stent will now be available in 40 European countries.
- see this story from The Wall Street Journal (sub. req.)